Search results
28 lut 2022 · IUD expulsions were analyzed in the full study cohort by postpartum timing interval at insertion and in the subcohort of women with breastfeeding status. We estimated incidence rates, cumulative incidence, and crude and adjusted hazard ratios (HRs) and their 95% CIs for risk of IUD expulsion.
29 kwi 2022 · The 52-mg levonorgestrel-releasing intrauterine system maintains an excellent safety profile and contraceptive efficacy through 8 years. For years 6 to 8, the 3-year Pearl Index (95% confidence interval) was 0.28 (0.03–1.00) with a 3-year cumulative failure rate of 0.68% (0.17–2.71).
Browse Mirena® (levonorgestrel-releasing intrauterine system) 52 mg IUD resources for you, your staff, & your patients. See full prescribing and safety info.
4 cze 2022 · The post-partum subcohort of individuals with breastfeeding information had 673 uterine perforations (62% complete), with a 5-year cumulative incidence of 1·37% (95% CI 1·24–1·52) and an increased risk with breastfeeding (aHR 1·37, 95% CI 1·12–1·66).
15 cze 2024 · Three hundred twenty lactating women were randomized to either an IUD containing levonorgestrel (Mirena; n = 163) or the copper-containing IUD Cu T380A group (n = 157). Follow-up of infants for 1 year found no differences in growth and development or in duration of breastfeeding.
22 lip 2009 · The levonorgestrel-releasing intrauterine system (LNG-IUS) has been available in Europe since 1990 and the United States since 2000. It is marketed under the name Mirena ® (Bayer Schering Pharma, Berlin, Germany). The LNG-IUS provides highly effective contraception for up to five years, with potential for approval for up to seven years in the ...
The post-partum subcohort of individuals with breastfeeding information had 673 uterine perforations (62% complete), with a 5-year cumulative incidence of 1·37% (95% CI 1·24–1·52) and an increased risk with breastfeeding (aHR 1·37, 95% CI 1·12–1·66).
